Saturday 17 October 2026
Export SBFM’s income statement to Excel — free account
Sunshine Biopharma, Inc.
SBFM Healthcare Drug Manufacturers Specialty & Generic
Sunshine Biopharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $36.3 million, up 4.11% from fiscal 2024. In the quarter to June 2026, revenue fell 1.56%, EPS grew 70.5% and free cash flow grew 49.4%, each against the same quarter a year earlier. Revenue growth for five consecutive years.
0.22
0.01
−4.35%
Follow SBFM
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.33 | 0.00 | 0.00 | 0.00 |
P/S ratio |
0.18 | 0.14 | 0.14 | 0.08 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(9.09) | (3.16) | (2.46) | (3.12) | |
P/B ratio |
0.28 | 0.22 | 0.24 | 0.10 | |
Price to Tangible BV |
0.31 | 0.24 | 0.26 | 0.11 | |
EV/Sales |
(0.02) | (0.06) | 0.00 | (0.25) | |
EV/EBITDA |
0.13 | 0.51 | 0.00 | 1.85 | |
EV/Operating CF |
0.09 | 0.40 | (0.02) | 1.68 | |
EV/FCF |
0.08 | 0.34 | (0.01) | 1.62 | |
Quick Ratio |
2.02 | 1.95 | 1.86 | 3.16 | |
Current Ratio |
4.20 | 4.17 | 4.22 | 5.46 | |
Net Debt/EBITDA |
21.36 | 5.85 | 5.24 | 8.96 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
1.21 | 1.20 | 1.24 | 1.08 | |
Operating CF/Net income |
0.84 | 0.75 | 1.67 | 0.59 | |
Capex/Depreciation |
(0.04) | (0.22) | (1.36) | (0.07) | |
Research and Development Expense of Revenue |
1.27% | 0.86% | 0.39% | 0.14% | |
Selling, General and Administrative Expense of Revenue |
36.00% | 73.02% | 42.87% | 42.62% | |
Intangible Assets out of Total Assets |
0.06 | 0.06 | 0.07 | 0.05 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 1.05% | |
Graham Net Nets |
3.05 | 3.87 | 3.60 | 8.57 | |
Graham Number |
233.15 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
305.42% | (120.33%) | (124.04%) | (483.33%) | |
Free Cash Flow Yield |
(117.91%) | (120.62%) | (126.16%) | (193.10%) | |
Revenue per Share |
20.67 | 20.63 | 16.49 | 6.79 | |
Operating CF per Share |
(1.64) | (3.89) | (4.22) | (0.67) | |
Capex per Share |
(0.05) | (0.12) | (0.21) | 0.00 | |
Free Cash Flow per Share |
(1.69) | (4.01) | (4.44) | (0.68) | |
Cash per Share |
20.43 | 21.95 | 14.09 | 10.07 | |
Shareholders Equity per Share |
53.12 | 55.42 | 43.86 | 20.17 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
53.12 | 55.42 | 43.86 | 20.17 | |
Free Cash Flow |
(0.77) | (1.67) | (2.18) | (0.92) | |
Working Capital |
21.32 | 20.41 | 18.91 | 25.05 | |
Capital Expenditures |
(0.02) | (0.05) | (0.10) | (0.01) | |
Net Current Asset Value |
20.68 | 19.81 | 18.37 | 24.57 | |
EV/EBIT |
0.09 | 0.34 | 0.00 | 1.53 | |
Capex to Sales |
0.00 | 0.01 | 0.01 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
3.69 | 3.66 | 3.73 | 3.81 | |
Average Payables |
5.15 | 5.60 | 5.06 | 4.83 | |
Average Inventory |
11.94 | 12.38 | 12.51 | 12.57 | |
Average Assets |
30.77 | 30.32 | 28.56 | 32.80 | |
Average Common Equity |
24.61 | 23.26 | 22.10 | 26.60 |
Columns are period end dates